SLC52A1

Across TCGA pan-cancer cohorts, SLC52A1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC52A1 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC52A1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SLC52A1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SLC52A1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.746	0.217	.008	9	view →
CCRCC	DFS	Median	II,III,IV	0.496	0.811	.014	8	view →
LUAD	OS	Quartile	II,III,IV	0.888	0.565	.030	7	view →
LSCC	DFS	Tertile	All	0.986	0.907	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC52A1–PDAC (OS)

Open the PDAC breakdown →